Rationales and choices for the treatment of patients with NYHA class II heart failure.

about

Rationales and choices for the treatment of patients with NYHA class II heart failure.

Item

http://www.wikidata.org/entity/Q39410727

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Rationales and choices for the treatment of patients with NYHA class II heart failure.

@en

Rationales and choices for the treatment of patients with NYHA class II heart failure.

@nl

type

Item

label

Rationales and choices for the treatment of patients with NYHA class II heart failure.

@en

Rationales and choices for the treatment of patients with NYHA class II heart failure.

@nl

prefLabel

Rationales and choices for the treatment of patients with NYHA class II heart failure.

@en

Rationales and choices for the treatment of patients with NYHA class II heart failure.

@nl

P1476

Rationales and choices for the treatment of patients with NYHA class II heart failure.

@en

P2093

Edward M Gilbert

http://www.w3.org/2001/XMLSchema#string

Weining David Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data

Advances in the epidemiology of heart failure and left ventricular remodeling

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

Determinants of adherence to heart failure medication: a systematic literature review

Digoxin-associated mortality: a systematic review and meta-analysis of the literature

Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure

From ARB to ARNI in Cardiovascular Control

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Increased mortality after dronedarone therapy for severe heart failure

P304

619-631

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2017.1344082

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28670961

http://www.w3.org/2001/XMLSchema#string